Revitope

Revitope

Biotechnology, 610 Main Street, Cambridge, Massachusetts, 01742, United States, 11-50 Employees

revitope.com

  • LinkedIn

phone no Phone Number: 16*********

Who is REVITOPE

Revitope is an early stage biotechnology company focused on developing the next-generation of T cell redirecting biologics. Immune-based therapies are redefining how cancer is treated as ...

Read More

map
  • 610 Main Street, Cambridge, Massachusetts, 01742, United States Headquarters: 610 Main Street, Cambridge, Massachusetts, 01742, United States
  • 2016 Date Founded: 2016
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $5 Million to $10 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 8069 | NAICS Code: 622310 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from REVITOPE

Revitope Org Chart and Mapping

Employees
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Revitope

Answer: Revitope's headquarters are located at 610 Main Street, Cambridge, Massachusetts, 01742, United States

Answer: Revitope's phone number is 16*********

Answer: Revitope's official website is https://revitope.com

Answer: Revitope's revenue is $5 Million to $10 Million

Answer: Revitope's SIC: 8069

Answer: Revitope's NAICS: 622310

Answer: Revitope has 11-50 employees

Answer: Revitope is in Biotechnology

Answer: Revitope contact info: Phone number: 16********* Website: https://revitope.com

Answer: Revitope is an early stage biotechnology company focused on developing the next-generation of T cell redirecting biologics. Immune-based therapies are redefining how cancer is treated as clinical studies demonstrate unprecedented deep and durable responses in multiple cancers. In particular redirecting T cells to tumors is a successful strategy for immunotherapy of liquid tumors. However, unleashing a potent immune response that is entirely focused on the tumor continues to be elusive. Revitope is developing a new class of biologic prodrugs we call Programmable Antibody Circuits or PACs that are engineered to focus immune activation to the cancer cell surface while expanding the antigenic targeting space.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access